GENVOYA 150mg/150mg/200mg/10mg COMPRIMIDOS RECUBIERTOS CON PELICULA

USDailyMed:Tenofovir alafenamide AU:B3 J05AF13(WHO) Combination codes:J05AR17(WHO)J05AR18(WHO)J05AR19(WHO)J05AR20(WHO)J05AR22(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) Isopropyl (2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]propanoate 379270-37-8 9574768 DB09299 7849225 EL9943AG5J D10428 CHEBI:90926 ChEMBL2107825 DTXSID50958941 Interactive image C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3 InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1Key:LDEKQSIMHVQZJK-CAQYMETFSA-N Tenofovir alafenamide(TAF), sold under the brand nameVemlidy, is anantiviralmedication used againsthepatitis BandHIV. It is used for the treatment ofchronic hepatitis B virus(HBV) infection in adults withcompensated liver diseaseand is given in combination with other medications for the prevention and treatment of HIV. It is takenby mouth. Tenofovir alafenamide is anucleotide reverse transcriptase inhibitorand is aprodrugoftenofovir. It was developed byGilead Sciencesbased on theprotidetechnology of Chris McGuigan and is applied in the form of tenofovir alafenamidefumarate(TAF). Closely related to the commonly used reverse-transcriptase inhibitortenofovir disoproxil fumarate(TDF), TAF has greater antiviral activity and better distribution intolymphoid tissuesthan that agent.It was approved for use in the US for HIV in 2015,and for hepatitis B in 2016.Although the USFood and Drug Administration(FDA) has approved tenofovir alafenamide for manufacture as ageneric medication,it is not available. A generic combination ofEmtricitabine/tenofovir alafenamide (Viatris) received marketing authorization in the European Union in July 2025.